

X#CARDIOTOX **CARDIOTOX.ES**

CARDIOTOX 26

12-13 NOVEMBER

MADRID



VENUE

Meeting Place Castellana 81, Madrid

Thursday, 12th November

08:30 – 09:00 **Welcome and registration**

09:00 – 09:10 **Inauguration**

Teresa López-Fernández, Cardiologist, Madrid

Raúl Córdoba, Hematologist, Madrid

Isabel Rodríguez, Radiation oncologist, Madrid

Álvaro Pinto, Medical oncologist, Madrid

09:10 – 09:50 **CARDIO-ONCOLOGY IN 2026**

Translating cardio-oncology advances into clinical care

Chairs:

Javier de Castro, Medical oncologist, Madrid

Raúl Córdoba, Hematologist, Madrid

Isabel Rodríguez, Radiation oncologist, Madrid

09:10 – 09:25 Cardio-oncology 2026: key advances for the clinic

Teresa López-Fernández, Cardiologist, Madrid

09:25 – 09:40 Proton therapy: is the heart still at risk?

Marianne Aznar, Radiation Oncology Physics, Manchester

09:40 – 09:50 Discussion

09:50 – 10:45 **FROM BENCH TO BEDSIDE**

Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events

Chairs:

Carlo Gabriele Tocchetti, Cardiologist, Naples

Virginia Calvo, Medical oncologist, Madrid

09:50 – 10:00 Mechanisms of ICI-related myotoxicity

Pilar Martín, Biologist, Madrid

10:00 – 10:10 ICI myotoxicity: from mechanisms to targeted treatment

Joe-Elie Salem, Cardiologist, Paris

10:10 – 10:20 Translational biomarkers in immune-related cardiotoxicity: from inflammatory cells to risk stratification

María Rosaria Galdiero, Clinical immunologist, Naples

10:20 – 10:30 T cell-based cancer therapies and associated cardiac irAEs

Lorenz Lehmann, Cardiologist, Heidelberg

10:30 – 10:45 Discussion

10:45 – 11:15

Coffee break

11:15 – 12:00

MEET THE EXPERTS

Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance.

Chairs:

Virginia Calvo, Medical oncologist, Madrid

Pedro Moliner, Cardiologist, Barcelona

11:15 – 11:25

ICI rechallenge after myocarditis: time for reassessment?

Joe-Elie Salem, Cardiologist, Paris

11:25 – 11:35

EGFR-targeted therapies: cardiovascular toxicity and monitoring

Oliver Higuera, Medical oncologist, Madrid

11:35 – 11:45

ALK inhibitors: practical surveillance and metabolic management

Dolores Isla, Medical oncologist, Zaragoza

11:45 – 12:00

Discussion

12:00 – 12:40

IN FOCUS

Tyrosine kinase inhibitors in CML: balancing vascular risk and treatment efficacy

Chairs:

Valentín García, Hematologist, Madrid

Marta Fanlo Maresma, Internal Medicine, Barcelona

Panel discussion:

Santiago Osorio, Hematologist, Madrid

Pilar Agudo, Cardiologist, Madrid

Juan Pedro Justel, General practitioner, Madrid

12:40 – 13:40

CARDIAC IMAGING IN CARDIO-ONCOLOGY

Imaging-led decisions in cardio-oncology: when to act? when to wait?

Chairs:

Victoria Delgado, Cardiologist, Barcelona

Pilar Zamora, Medical oncologist, Madrid

12:40 – 12:50

GLS drop: treat or observe?

Belén Terol, Cardiologist, Madrid

12:50 – 13:00

CMR: When does it alter therapy?

Rocío Eiros, Cardiologist, Salamanca

13:00 – 13:10

CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls

Chiara Bucciarelli-Ducci, Cardiologist, London

13:10 – 13:20

Asymptomatic ASCVD in cancer survivorship: what next?

Inés García Lunar, Cardiologist, Madrid

13:20 – 13:40

Discussion

13:40 – 15:30

Lunch break: Tutorials / Satellite Symposium

15:30 – 16:30

FROM BENCH TO BEDSIDE

The vicious cycle of cancer therapy-induced cardiac injury: mechanisms and treatment windows

Chairs:

Lorenz Lehmann, Cardiologist, Heidelberg

Inés García Lunar, Cardiologist, Madrid

15:30 – 15:40

Anthracycline cardiotoxicity: molecular mechanisms that inform prevention

Alessandra Ghigo, Cardiologist, Torino

15:40 – 15:50

Exercise in CTRCD: mechanistic rationale and treatment windows

Carlo Gabriele Tocchetti, Cardiologist, Naples

15:50 – 16:00

Neurohormonal inhibition in CTRCD: preclinical and clinical evidence

Pietro Ameri, Cardiologist, Genoa

16:00 – 16:10

Reversible vs irreversible CTRCD: biological continuum or distinct entities?

Dimitrios Farmakis, Cardiologist, Athens

16:10 – 16:30

Discussion

-
- 16:30 – 17:30** **CLINICAL CASE FORUM**
Acute cardio-oncology: are we ready for the 24-hour challenge?
Chairs:
Eduardo Zatarain, Cardiologist, Madrid
Pietro Ameri, Cardiologist, Genoa
- 16:30 – 16:45** ICI-myotoxicity: early signals and grey zones
Jorge Álvarez Troncoso, Internal Medicine, Madrid
- 16:45 – 17:00** Acute coronary syndrome during cancer treatment
Pedro Moliner, Cardiologist, Barcelona
- 17:00 – 17:15** Cardiovascular complications of CRS in CAR-T therapy
Annamaria Brioli, Hematologist, Hannover
- 17:15 – 17:30** Acute pulmonary embolism in cancer: when to escalate
Sandra Rosillo, Cardiologist, Madrid
-

- 17:30 – 19:00** **TUTORIALS / SATELLITE SYMPOSIUM**

Friday, 13th November

08:30 – 09:15

SYMPOSIUM

Cardiovascular risk across cancer therapies and survivorship

Chairs:

Peter van der Meer, Cardiologist, Groningen

Cristina Mitroi, Cardiologist, Madrid

08:30 – 08:40

Cardiovascular risk with immunotherapy-based combinations

TBC

08:40 – 08:50

Endocrine and targeted therapies in breast cancer: the unresolved long-term cardiovascular burden

Jutta Bergler-Klein, Cardiologist, Vienna

08:50 – 09:00

Biomarkers for risk stratification and long-term surveillance

Daniela Cardinale, Cardiologist, Milan

09:00 – 09:15

Discussion

09:15 – 10:00

IN FOCUS

Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies

Chairs:

Chiara Bucciarelli-Ducci, Cardiologist, London

Dimitrios Farmakis, Cardiologist, Athens

09:15 – 09:25

Clinical and imaging red flags

Rocío Eiros, Cardiologist, Salamanca

09:25 – 09:35

ATTR cardiac amyloidosis: recent therapeutic advances

Peter van der Meer, Cardiologist, Groningen

09:35 – 09:45

AL cardiac amyloidosis: emerging treatment strategies and cardiac outcomes

Annamaria Brioli, Hematologist, Hannover

09:45 – 10:00

Discussion

-
- 10:00 – 11:00** **CLINICAL CASE FORUM**
Vascular and valvular cardio-oncology: recognition, timing and management priorities
Chairs:
Pilar Zamora, Medical oncologist, Madrid
Victoria Delgado, Cardiologist, Barcelona
- 10:00 – 10:15** Fluoropyrimidine-associated chest pain: acute management and next steps
Cristina Contreras, Cardiologist, Madrid
- 10:15 – 10:30** Severe aortic stenosis in active cancer: timing TAVI and competing clinical priorities
Amparo Martínez Monzonis, Cardiologist, Santiago de Compostela
- 10:30 – 10:45** When anticoagulation leads to bleeding: what to do and when to act?
Cristina Pascual, Hematologist, Madrid
- 10:45 – 11:00** CV surveillance after HSCT: defining who is truly high-risk
Irene Sánchez Vadillo, Hematologist, Madrid
- 11:00 – 11:30** **Coffee break**
-
- 11:30 – 12:30** **FROM BENCH TO BEDSIDE**
Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
Chairs:
Cristina Mitroi, Cardiologist, Madrid
Álvaro Pinto, Medical oncologist, Madrid
- 11:30 – 11:40** CHIP as a cardiovascular risk modifier: what matters in cardio-oncology?
José Javier Fuster, Biochemist, Madrid
- 11:40 – 11:50** CHIP in lymphoma: biological links and implications for cardiac injury
Miguel Canales, Hematologist, Pamplona
- 11:50 – 12:00** TTN truncating variants before anthracycline therapy: proceed, modify or protect?
Juan Caro, Cardiologist, Madrid
- 12:00 – 12:10** Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis
Rebeca Lorca, Cardiologist, Oviedo
- 12:10 – 12:30** Discussion

12:30 – 13:15

MEET THE EXPERTS

Anticipating and managing cardiovascular risk in patients with prostate and renal cancer

Chairs:

Álvaro Pinto, Medical oncologist, Madrid

Sergio Cinza, General practitioner, Santiago de Compostela

12:30 – 12:40

Cardiovascular adverse events with tyrosine-kinase inhibitors for renal cancer

Guillermo de Velasco, Medical oncologist, Madrid

12:40 – 12:50

Hormone therapy for prostate cancer and cardiovascular toxicity

Natalia Vidal, Medical oncologist, Madrid

12:50 – 13:00

Pre-treatment assessments in patients with prostate cancer

Estefanía Linares, Urologist, Madrid

13:00 – 13:15

Discussion

13:15 – 14:00

IN FOCUS

BTK inhibitors in CLL: new strategies, new cardiovascular questions

Chairs:

Raúl Córdoba, Hematologist, Madrid

Rebeca Lorca, Cardiologist, Oviedo

13:15 – 13:25

Real-world evidence: beyond clinical trials

TBC

13:25 – 13:35

Finite vs continuous treatment: cardiovascular risk after treatment discontinuation

Lucrecia Yáñez, Hematologist, Santander

13:35 – 13:45

Non-covalent BTK inhibitors: a new drug class with a favourable cardiovascular safety profile

José Ángel Hernández Rivas, Hematologist, Madrid

13:45 – 14:00

Discussion

14:00 – 15:30

Lunch break: Tutorials / Satellite Symposium

CARDIOTOX 26

12-13 NOVEMBER
MADRID

VENUE Meeting Place Castellana 81, Madrid

- 15:30 – 16:30** **CLINICAL CASE FORUM**
Prevention and permissive cardiotoxicity: are we doing too much or too little?
Chairs:
Vicente Pallarés, General practitioner, Castellón
Ana Martín, Cardiologist, Salamanca
- 15:30 – 15:40 Obesity in cancer care: ignore or treat from day one?
Almudena Castro, Cardiologist, Madrid
- 15:40 – 15:50 Albuminuria during VEGF inhibition: marker or mandate to act
Pilar Mazón, Cardiologist, Santiago de Compostela
- 15:50 – 16:00 Permissive cardiotoxicity: LVEF-led or context-led decision-making?
Eduardo Zatarain, Cardiologist, Madrid
- 16:00 – 16:10 Myocardial injury in acute leukaemia: a triple-hit of host, disease, and treatment
Gabriela Rodríguez Macías, Hematologist, Madrid
- 16:10 – 16:30 Discussion
-
- 16:30 – 17:30** **SYMPOSIUM**
Building the roadmap for the next generation of cardio-oncology care
Chairs:
Raúl Córdoba, Hematologist, Madrid
Teresa López-Fernández, Cardiologist, Madrid
- 16:30 – 16:45 Translational research priorities in cardio-oncology
Borja Ibáñez, Cardiologist, Madrid
- 16:45 – 17:00 Cardio-oncology roadmap: from trials and real-world data to future guidelines
Alexander Lyon, Cardiologist, London
- 17:00 – 17:15 Discussion
-
- 17:15 – 17:30** **CLOSING REMARKS**

CARDIOTOX 26

12-13 NOVEMBER
MADRID



Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net